29 August 2017
Maxim Gorbachev, Managing Partner of RMI Partners: "New technologies make dramatic changes to business. They even reached financing of venture capital companies. Use of crypto-currency has resulted into development of the new mechanism of crowdfunding – Initial Coin Offering (ICO) which is in a way similar to public share placement (IPO). Venture projects utilize blockchain technologies to create and sell digital tokens, thus raising funds from investors. When initially ICO was used as mechanism to develop new crypto-currency instruments such as Ethereum, nowadays ICO serve as a democratic mechanism of fund raising for any project. And this instrument cannot be ignored due to amounts of funds raised this way."
11 August 2017
Rustam Iksanov, who used to hold one of the managerial positions in Valenta Pharma, has been appointed as R&D Vice President of pharmaceutical company NovaMedica.
29 May 2017
Russian pharmaceutical company NovaMedica, a portfolio company of RUSNANO, announces the appointment of Alexander Kuzin to the post of General Director (CEO). This decision has taken unanimously by the Board of Directors of NovaMedica on May 26, 2017.
17 November 2017
To ensure the quality and safety of drugs, biologics, and medical products more efficiently and effectively, FDA is making significant changes in its plant inspection program, including more attention to imports and to foreign producers of drugs for American consumers. An aim is to target manufacturing oversight to more high-risk operations and free up resources for greater scrutiny of foreign facilities in the process.
16 November 2017
The European Medicines Agency (EMA) and the European Network for Health Technology Assessment (EUnetHTA) have published a joint work plan outlining key areas of collaboration for the next three years.
16 November 2017
U.S. regulators have approved the first digital pill with an embedded sensor to track if patients are taking their medication properly, marking a significant step forward in the convergence of healthcare and technology.
15 November 2017
The gene editing system CRISPR-Cas9 has generated excitement for its potential use in eliminating disease-causing irregularities in DNA. But most CRISPR systems rely on viruses to carry Cas9 components into cells, where they then go to work cutting DNA.